MSD secures full approval for Keytruda’s use in MSI-high solid tumours
Pharmaceutical Technology
MARCH 30, 2023
Broadening uses and secured full approvals Since its first approval in September 2014, Keytruda has achieved blockbuster status on the market. There, the FDA suggested that the drugs undergo randomised controlled trials, which the document describes as the preferred approach, rather than single-arm trials.
Let's personalize your content